NSE filing, NSE: SAROJA. Summary written from the filing by ALFA Finder's alert engine.
Saroja Pharma Industries India Ltd: key numbers
- Share price
- ₹38.80
- Market cap
- ₹15.60 Cr
- Revenue (annual)
- ₹70.13 Cr
- Net profit (annual)
- ₹1.61 Cr
- P/E (TTM)
- 9.7×Sector 28.2×
- Promoter holding
- 73.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saroja Pharma Industries India Ltd
All →Saroja Pharma Industries India Management Change
Saroja Pharma's statutory auditor Pravin Chandak & Associates resigned effective October 26, 2026, citing pre-occupation. The company will appoint new auditors to fill the vacancy.
Saroja Pharma Industries India Management Change
Mr. Ravindra Shivaji Salaskar has resigned as Whole-time Director of Saroja Pharma Industries India Limited, effective October 5, 2026. He continues as the company's CFO.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited held its 8th Annual General Meeting on September 30, 2026, through video conferencing to transact business.
Saroja Pharma Industries India Management Change
Saroja Pharma Industries India Limited appointed Mr. Ravindra Shivaji Salaskar as Chief Financial Officer. He currently serves as a Whole-time Director of the company.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited has issued a notice for its 8th Annual General Meeting, scheduled to be held on September 30, 2026, through video conferencing.
Saroja Pharma Industries India Board Meeting Outcome
Saroja Pharma Industries approved its draft Board Report, Management Discussion and Analysis Report, and the notice for its 8th Annual General Meeting.
Other board meeting outcome announcements
All →Jiwanram Sheoduttrai Industries Board Meeting Outcome
Jiwanram Sheoduttrai's board approved convening its 29th AGM on 30 November 2026 and re-appointing a retiring non-executive director. The board also approved the FY2025-26 Board's Report.
Finolex Cables Board Meeting Outcome
Finolex Cables' board approved amending its insider trading code of conduct on 7 November 2026. Amended code was filed under PIT Regulation 8(2).
Chatterbox Technologies Board Meeting Outcome
Chatterbox's board approved a Rs. 7 crore related-party ceiling with its UAE subsidiary and a vendor change for IPO funds. Monitoring agency and deviation reports were also noted.
BCC Fuba India Board Meeting Outcome
BCC Fuba India's board met on November 6, 2026 and took note of consolidated related party transactions for the half year ended September 30, 2026. No financial results, capital raise or other material decision was reported.
Voltas Board Meeting Outcome
Voltas Limited's board approved Deloitte Haskins & Sells as statutory auditors for five years from the 73rd AGM, replacing SRBC & Co. LLP, whose second and final term ends at that AGM. Subject to shareholder approval.
- Execution
- Five years: financial years 2027-28 to 2031-32 (from the 73rd AGM in 2027 to the 78th AGM in 2032)
CMX Holdings Board Meeting Outcome
Riwind Green Energy (formerly CMX Holdings) board approved altering its MOA main objects into six consolidated objects and a postal ballot notice. The change refocuses the company on solar, EPC, battery storage and renewable data-centre businesses.